Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-09-06 pm EDT 5-day change 1st Jan Change
6.210 USD +0.32% Intraday chart for Bausch Health Companies Inc. +4.72% -22.57%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Milestone Pharmaceuticals Appoints Joseph Papa to Its Board of Directors CI
Health Care Up on Lilly's Blockbuster Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
Sector Update: Health Care MT
Bausch Health Eye-Care Unit Spinoff Stalls Amid Shareholders, Creditors Disagreement MT
Bausch Health's Eye-Care Unit Spinoff Stalled Amid Shareholders' Dispute With Creditors, WSJ Reports MT
RBC Cuts Bausch Health Price Target to US$8.50, Maintains Sector Perform MT
TSX hits over three-week low as US jobs data adds to recession worries RE
Exchange-Traded Funds, Equity Futures Lower Pre-Bell as Technology Stocks, July Jobless Rate Raise Investor Concerns MT
RBC Cuts Price Target on Bausch Health to $8.50 From $10, Keeps Sector Perform Rating MT
Top Premarket Decliners MT
Piper Sandler Downgrades Bausch Health to Underweight From Neutral, Adjusts Price Target to $3 From $9 MT
Bausch Health Companies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
Bausch Health Shares Rise Following Q2 Results, Higher 2024 Outlook MT
Bausch Health Q2 Adjusted Profit Declines, Revenue up 11%; Revenue Guidance Raised MT
Transcript : Bausch Health Companies Inc., Q2 2024 Earnings Call, Aug 01, 2024
Bausch Health Brief: Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP) guidance MT
Correction: -- Bausch Health Brief: Q2 consolidated revenues of US$2.40 billion; Consolidated GAAP Net Income Attributable $10 million MT
Bausch + Lomb Brief: Q2 consolidated revenues of US$2.40 billion; Consolidated GAAP Net Income Attributable $10 million MT
Bausch + Lomb Brief: Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP) Guidance MT
Bausch + Lomb Brief: Q2 GAAP Net Loss Attributable of US$151 Million MT
Bausch + Lomb Brief: Q2 Revenue of US$1.216 Billion MT
Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024 CI
Truist Adjusts Bausch Health Companies' PT to $7 From $8, Maintains Hold Rating MT
Toronto stocks fall as tech selloff counters BoC rate cut RE
Chart Bausch Health Companies Inc.
More charts
Logo Bausch Health Companies Inc.
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Employees
20,270
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
6.210USD
Average target price
7.786USD
Spread / Average Target
+25.37%
Consensus
  1. Stock Market
  2. Equities
  3. BHC Stock
  4. News Bausch Health Companies Inc.
  5. Sector Update: Health Care Stocks Rise in Late Afternoon Trading
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW